Simvastatin in Patients With Septic Shock

The recruitment status of this study is unknown because the information has not been verified recently.

Verified September 2007 by Medical University of Vienna.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Medical University of Vienna

ClinicalTrials.gov Identifier:

NCT00450840

First received: March 21, 2007

Last updated: September 14, 2007

Last verified: September 2007

History of Changes

Purpose

The beneficial effect of statins to prevent cardiovascular events in patients at risk is well established. Recent trials demonstrated that statins can exert a number of vascular actions independent of lipid lowering. Short-term simvastatin therapy recently has been reported to reduce mortality in 2 different animal models of sepsis. Pleiner and coworkers could demonstrate potent vasoprotective properties of simvastatin during Escherichia coli endotoxin induced endotoxemia in healthy volunteers. In a population-based cohort analysis it was demonstrated that administration of statins was associated with a reduced risk of subsequent sepsis. Thus, simvastatin treatment may offer a new therapeutic strategy for clinical conditions associated with inflammation like severe sepsis and septic shock. The aim of the present study is to test the hypothesis that short term treatment with simvastatin may mitigate the detrimental vascular effects of acute inflammation in patients admitted to the intensive care unit requiring treatment for septic shock.

Condition	Intervention	Phase
Septic Shock	Drug: Simvastatin	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Shock

Drug Information available for: Simvastatin

U.S. FDA Resources

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:

Time to shock reversal as defined by cessation of vasopressor support > 1 hour

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age > 18 years
Septic Shock for less than 48 hours

Exclusion Criteria:

Pregnancy
Unable to receive enteral medications
Expected survival of less than 72 hours
Treatment in the previous 3 weeks with simvastatin or other HMG-CoA reductase inhibitors
History of hypersensitivity to the trial drug or to drugs with a similar chemical structure
History of known or suspected porphyria
High risk of rhabdomyolysis (multiple trauma, crush injuries, extensive burns, baseline creatinine kinase (CK) ≥ten-times upper limit of normal
Hemorrhagic shock

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00450840

Contacts


Contact: Peter Schenk, MD	0043-1-40400 ext 4767	peter.schenk@meduniwien.ac.at

Locations


Austria
Medical University of Vienna, Dep. of Internal Medicine III	Recruiting
Vienna, Austria, 1090
Contact: Valentin Fuhrmann, MD 0043-1-40400 ext 4767 valentin.fuhrmann@meduniwien.ac.at
Sub-Investigator: Valentin Fuhrmann, MD

Sponsors and Collaborators

Medical University of Vienna

Investigators


Principal Investigator:	Peter Schenk, MD	Medical University of Vienna, Intensive Care Unit

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Dobesh PP, Olsen KM. Statins role in the prevention and treatment of sepsis. Pharmacol Res. 2014 Oct;88:31-40. doi: 10.1016/j.phrs.2014.04.010. Epub 2014 May 2. Review.


ClinicalTrials.gov Identifier:	NCT00450840 History of Changes
Other Study ID Numbers:	3732006
Study First Received:	March 21, 2007
Last Updated:	September 14, 2007
Health Authority:	Austria: Agency for Health and Food Safety

Keywords provided by Medical University of Vienna:


septic shock simvastatin

Additional relevant MeSH terms:


Shock Shock, Septic Pathologic Processes Sepsis Infection Systemic Inflammatory Response Syndrome Inflammation Simvastatin	Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors

ClinicalTrials.gov processed this record on September 29, 2016

To Top